Infliximab induced liver injury in Crohn's disease: A challenging diagnosis
| Autor: | Joana Carvalheiro, Carlos Sofia, Sofia Mendes |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Budesonide
medicine.medical_specialty Abdominal pain Crohn's disease medicine.diagnostic_test business.industry Doença de Crohn Gastroenterology Azathioprine Physical examination General Medicine medicine.disease Asymptomatic Infliximab Surgery chemistry.chemical_compound Mesalazine chemistry medicine Doença Hepática Induzida por Medicamentos medicine.symptom business medicine.drug |
| Popis: | Dear Sir, A 24-year-old male patient with a 6-year history of Crohn's disease (A2L1B2, Montreal classification),1 in remission for 4 years with mesalazine, was admitted in September 2010 complaining of abdominal pain and cramps. Physical examination revealed slight and diffuse abdominal pain. Entero-magnetic resonance revealed terminal ileitis and, thus, budesonide (9 mg/day) and azathioprine (2.5 mg/kg/day) were started. Nevertheless, the patient presented 12% of weight loss in 7 months. In April 2011, abdominal ultrasound showed persistent bowel loop wall thickening. Infliximab 5 mg/kg was added to azathioprine in May 2011 and the patient became rapidly asymptomatic, presenting 10 kg weight gain. … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|